Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose
concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo
(vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).